DK0538341T3 - EHV-4-gycoproteinvaccine. - Google Patents

EHV-4-gycoproteinvaccine.

Info

Publication number
DK0538341T3
DK0538341T3 DK91912865.2T DK91912865T DK0538341T3 DK 0538341 T3 DK0538341 T3 DK 0538341T3 DK 91912865 T DK91912865 T DK 91912865T DK 0538341 T3 DK0538341 T3 DK 0538341T3
Authority
DK
Denmark
Prior art keywords
ehv
gycoproteinvaccine
polypeptides
fragments
presented
Prior art date
Application number
DK91912865.2T
Other languages
Danish (da)
English (en)
Inventor
Lesley Nicolson
David Edward Onions
Original Assignee
Univ Glasgow
Equine Virology Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, Equine Virology Res Found filed Critical Univ Glasgow
Application granted granted Critical
Publication of DK0538341T3 publication Critical patent/DK0538341T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91912865.2T 1990-07-06 1991-07-04 EHV-4-gycoproteinvaccine. DK0538341T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909014950A GB9014950D0 (en) 1990-07-06 1990-07-06 Ehv-4 glycoprotein vaccine

Publications (1)

Publication Number Publication Date
DK0538341T3 true DK0538341T3 (da) 1997-06-30

Family

ID=10678729

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91912865.2T DK0538341T3 (da) 1990-07-06 1991-07-04 EHV-4-gycoproteinvaccine.

Country Status (15)

Country Link
US (1) US6083511A (hu)
EP (1) EP0538341B1 (hu)
JP (1) JPH05509226A (hu)
AT (1) ATE147100T1 (hu)
AU (1) AU8200791A (hu)
CA (1) CA2086739A1 (hu)
DE (1) DE69123970T2 (hu)
DK (1) DK0538341T3 (hu)
ES (1) ES2099164T3 (hu)
GB (1) GB9014950D0 (hu)
GR (1) GR3023297T3 (hu)
HU (1) HU217211B (hu)
NZ (1) NZ238833A (hu)
WO (1) WO1992001057A1 (hu)
ZA (1) ZA915230B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
WO1993024528A1 (en) * 1992-06-01 1993-12-09 The University Of Melbourne Equine herpesvirus glycoproteins
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
US6225111B1 (en) 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
CN1125992A (zh) * 1993-04-14 1996-07-03 雷马克伊(控股)有限公司 可抹除的标志
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
AR040601A1 (es) * 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
US7323178B1 (en) 2004-01-16 2008-01-29 The Ohio Department Of Agriculture Method of identification of equine herpes virus type 1 causing neurological disease, method of producing a vaccine against neurological disease caused by equine herpes virus type 1, and vaccine against neurological disease caused by equine herpes virus type 1
EP2072620B1 (en) 2004-12-08 2013-05-08 SunGene GmbH Expression casstettes for vascular tissue-preferential expression in plants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine

Also Published As

Publication number Publication date
JPH05509226A (ja) 1993-12-22
EP0538341B1 (en) 1997-01-02
US6083511A (en) 2000-07-04
GB9014950D0 (en) 1990-08-29
GR3023297T3 (en) 1997-07-30
ATE147100T1 (de) 1997-01-15
EP0538341A1 (en) 1993-04-28
WO1992001057A1 (en) 1992-01-23
CA2086739A1 (en) 1992-01-07
DE69123970D1 (de) 1997-02-13
NZ238833A (en) 1993-02-25
DE69123970T2 (de) 1997-07-24
HU217211B (hu) 1999-12-28
ES2099164T3 (es) 1997-05-16
HUT69920A (en) 1995-09-28
HU9300009D0 (en) 1993-04-28
ZA915230B (en) 1992-04-29
AU8200791A (en) 1992-02-04

Similar Documents

Publication Publication Date Title
DK0757717T3 (da) Papillomavirusvacciner
DK0605442T3 (da) Rekombinante antistoffer til human terapi
ES2063515T3 (es) Ifn-alfa o-glucosilados.
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
HUT72187A (en) Recombinant method and host for manufacture of xylitol
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE3853743D1 (de) Rekombinanter menschlicher ADF.
IT1238202B (it) Proiettore ad inclinazione regolabile.
IT8920839A0 (it) Procedimento e dispositivo per la realizzazione di pannelli.
DE69122612D1 (de) Interleukin-4-bindeprotein-gamma
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
DK0511516T3 (da) Schizosaccharomyces-specifikke polypeptider
NO912192L (no) Rekombinante dna og fremgangsmaate for fremstilling av chimere antistoffer.
NO902021D0 (no) Fremstilling av cga-fragmenter inneholdende den n-terminale region og anvendelse derav.
IT8125642A0 (it) Procedimento per la duplicazione di sagome e finiture.
NO893458L (no) Fremgangsmaate og kakalysator for fremstilling av syntesegass.
IT216579Z2 (it) Dispositivo macinatore per pepe e simili.